Posters

Results of the amniotic membrane in a third level hospital

Poster Details

First Author: J.Lacorzana Rodriguez SPAIN

Co Author(s):    J. García Serrano   M. Alaminos Mingorance                 

Abstract Details

Purpose:

To evaluate the use of the amniotic membrane transplantation for ophthalmic purposes in the region of Granada (Spain) between 2013 and 2017 and to identify possible variables which could affect postoperative prognosis.

Setting:

Hospital Virgen de las Nieves, Granada

Methods:

Ours was a retrospective study of a serie of 44 cases, who received an amniotic membrane transplantion due to corneal diseases. The minimum follow-up period was 8 months. The indications of amniotic membrane transplantation were: chemical burn , descemetocele, corneal perforation, recurrent pterygium, band keratopathy, nummular keratitis, symblepharon, and recurrent ulcers. For the statistical analysis, the results of the success group were compared with those of the failure group using the Mann-Whitney test, applying the Kendall test to identify the correlation between groups.

Results:

Regarding the success or failure of the treatment, statistically significant differences were found between the success group and the failure group for the following variables: implant motive due to corneal perforation (most failed), the existence of complications and corneal transparency, which correlated positively or negatively with the success of the transplantation. About these last two parameters (the absence of complications and good corneal transparency) were related to postoperative success.

Conclusions:

This preliminary study suggests that amniotic membrane transplantation could be useful in ophthalmology, existing a clear association between the success of this technique and certain factors related to the evolution of the patient. Likewise, amniotic membrane should not be used in isolation in patients with ocular perforation, due to the high risk of failure of the technique. It is necessary to perform along with adjuvant treatments and recommended the study of more definitive treatments.

Financial Disclosure:

None